Japanese Chemical Makers Strengthens Overseas Medical Business To Offset Sluggish Chemical Demand
This article was originally published in PharmAsia News
Executive Summary
Amid the worldwide recession, several Japanese chemical companies strengthened their medical businesses to offset a sluggish demand for chemical and optical products. Asahi Chemical signed a co-development and promotion deal with Nagano-based medical device maker Misuzu Sun Medical Holdings for Evaheart left ventricular assist system for congestive heart failure patients in overseas markets. The company has submitted an application with FDA to start clinical trials in the U.S. Trials are also being planned in Europe in 2011. The company estimates ¥25 billion in sales by 2020. Sekisui Chemical is in negotiations to acquire a mid-sized U.S. company and expand its diabetes testing agent market. Teijin established a joint venture in Spain this February to strengthen its home care device business. (Click here for more - Japanese language